Skip to content
Review Open access

The Gut Microbiota-Associated Metabolite Network in Ischemic Stroke: From Pathophysiological Imbalance to Potential Precision Intervention Strategies

Nov 2026 · International Journal of General Medicine · Vol 19, pp. 1-44 · 0 citations · 279 references
Medicine

TL;DR

This review proposes “gut microbiota-associated metabolite network imbalance” as a conceptual, integrative, and hypothesis-generating framework for understanding IS pathophysiology, and summarizes current evidence on protective and injurious metabolite pathways, their crosstalk, and emerging therapeutic strategies.

Abstract

Abstract Ischemic stroke (IS) remains a leading cause of death and long-term neurological disability worldwide, and current treatment options are constrained by narrow therapeutic windows and limited neuroprotective efficacy. Accumulating evidence implicates the microbiota-gut-brain axis (MGBA) in the development and progression of IS. Following cerebral ischemia, bidirectional communication between the brain and gut is disrupted, resulting in gut microbial dysbiosis, impaired intestinal barrier function, and altered production of microbiota-associated metabolites that influence neuroinflammation, immune regulation, blood-brain barrier (BBB) integrity, and post-stroke recovery. Among these molecules, short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), bile acids (BAs), tryptophan-derived metabolites, and lipopolysaccharide (LPS) have attracted particular attention. Importantly, these molecules differ in origin: SCFAs and several tryptophan-derived indoles are direct microbial products; TMAO is a host-microbial co-metabolite; primary BAs are host-derived and subsequently modified by gut bacteria; and LPS is a bacterial structural component. Rather than acting in isolation, these metabolites form an interconnected network characterized by synergistic, antagonistic, compensatory, and feedback interactions; however, only a subset of these interactions has been directly demonstrated in patients with IS or in experimental stroke models, and many remain inferred from studies in other cardiovascular, metabolic, or inflammatory conditions. At present, the strongest human evidence concerns associations of individual metabolites with stroke risk and outcomes, whereas the proposed network-level interactions remain largely inferential. This review therefore proposes “gut microbiota-associated metabolite network imbalance” as a conceptual, integrative, and hypothesis-generating framework for understanding IS pathophysiology, and summarizes current evidence on protective and injurious metabolite pathways, their crosstalk, and emerging therapeutic strategies. Metabolite-guided precision intervention remains largely investigational and will require prospective validation before clinical translation.

Read PDF

Similar papers

Review Open access Oct 2026

TMAO at the Crossroads of the Gut–Brain Axis: Emerging Mechanisms Linking Microbiota-Derived Metabolites to Neuroinflammation and Cognitive Dysfunction

The potential use of TMAO and its precursors as therapeutic targets for multiple neurodegenerative disorders is suggested, however, the need for conducting large, adequately powered randomized clinical studies to determine its therapeutic relevance is emphasized.

Aseel Y. Altahrawi, F. Sofi, Zara Kanjwal et al. · 0 citations
Review Open access Nov 2026

Gut microbiota and its metabolites in diabetic kidney disease: underlying mechanisms and recent research breakthroughs

Diabetic kidney disease (DKD) stands as a paramount microvascular complication of diabetes, now recognized globally as the primary driver of end-stage renal disease. Recent years have witnessed intensive scrutiny into how gut microbiota, operating through the “gut–kidney axis,” orchestrate the onset and advancement of...

Yuan Yuan, Xin-Xin Pang, Ya-Chan Gao et al. · 0 citations
Review Open access Oct 2026

Beyond Neuroinflammation: Targeting the Microbe–Barrier–Brain Axis Through Precision Nutrition in Neurological Long COVID (Neuro-PASC)

Post-acute Neurological Sequelae of SARS-CoV-2 infection (Neuro-PASC) contribute substantially to Long COVID-related disability, with cognitive impairment, chronic fatigue, dysautonomia, and neuropsychiatric symptoms among its most debilitating manifestations. Although its pathogenesis remains incompletely understood,...

Amador Velázquez de Castro-Bono, G. Castro-Luna, J. Guil-Guerrero · 0 citations
Review Open access Oct 2026

Gut microbiome intervention in gut-brain axis and effects on vascular dementia with prospects on non-pharmacological intervention

Vascular dementia (VD) is the second leading cause of cognitive impairment after Alzheimer's disease. Current treatments focus primarily on managing vascular risk factors with no effective interventions for repairing existing brain damage. Recent research underscores a critical link between gut microbiota and brain fun...

Yash Maurya, Elizabeth Annie George, A. Roy et al. · 0 citations
Review Open access Oct 2026

Gut microbiota-driven imbalance of the gut-brain-immune homeostatic network in constipation: Pathogenic mechanisms and evolving therapeutic prospects

Summary Chronic constipation (CC) is increasingly recognized as a systems-level disorder that cannot be explained by impaired intestinal motility alone. Here, we integrate evidence from clinical cohorts, animal models, and mechanistic studies to examine how gut microbial dysbiosis and altered microbial metabolites pert...

Jia-Ning Zhu, Bin-Bin Zeng, Wen-Xu Zhu et al. · 0 citations
Nov 2026

Gut Microbiota-Brain Axis in Type 2 Diabetes Mellitus: Association with Neuroinflammation and Cognitive Dysfunction

Diabetes mellitus Type 2 (T2DM) is a metabolic disorder that is now emerging as a risk factor for cognitive dysfunction, neuroinflammation, and gut microbiota changes. The gut microbiota – brain axis is a bidirectional communication system with links between intestinal microorganisms and the central nervous system via...

Ahsan Ali Khan · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.